Poseida to Present Data on CAR-T Cell Therapies at SITC and ASH 2024

Poseida Therapeutics, a clinical-stage company specializing in allogeneic cell therapy and genetic medicines, has announced significant developments in their research on allogeneic CAR+TCR-T cells. The company will present their new preclinical data at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston from November 6-10, 2024. These data focus on allogeneic CAR+TCR-T cells that are enriched with stem cell memory T cells (TSCM), designed to enhance potency and improve targeting of solid tumors.

Furthermore, Poseida will also present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition scheduled for December 7-10 in San Diego. The presentations will include additional profiling of patient responses from the optimized lymphodepletion arm (Arm C) of the P-BCMA-ALLO1 Phase 1 study. This data was initially introduced at the 21st International Myeloma Society (IMS) Annual Meeting. Additionally, preclinical data from the ongoing Phase 1 trial of P-CD19CD20-ALLO1 in patients with B-cell malignancies will also be featured.

The investigational therapies P-BCMA-ALLO1 and P-CD19CD20-ALLO1 are central to Poseida’s research focus. P-BCMA-ALLO1, a non-viral TSCM-rich allogeneic CAR-T therapy currently in Phase 1/1b clinical trials, targets BCMA in patients with relapsed or refractory multiple myeloma. This therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation for patients who have undergone at least three prior lines of therapy. P-CD19CD20-ALLO1, Poseida’s first allogeneic dual CAR-T cell therapy, targets both CD19 and CD20 antigens and is being developed for relapsed or refractory B-cell malignancies. This therapy aims to address the limitations of CD19-only targeted CAR-T therapies by targeting both antigens simultaneously.

Poseida's participation in the SITC meeting will include a poster presentation titled "Multi-antigen Targeting with CAR and TCR Co-expression in Allogeneic Cell Therapy for Solid Tumors" presented by Dr. Sergio M. Quinones-Parra on November 9, 2024. This presentation will shed light on the potential of multi-antigen targeting to enhance the efficacy of allogeneic cell therapies in treating solid tumors.

At the ASH meeting, Poseida will present several posters, including one titled "Late Polyclonal P-BCMA-101 CAR-T Cell Re-expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Years After CAR-T Infusion" by Dr. Anupama Kumar. Another notable presentation is "P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy Over Single-Target Products" by Dr. Samy Jambon, which will highlight the dual targeting efficacy of P-CD19CD20-ALLO1 over single-target therapies. Additionally, Dr. Caitlin Costello will present data on the optimized lymphodepletion cohort of P-BCMA-ALLO1 in a session titled "A Phase 1 Study of P-BCMA-ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort."

Poseida Therapeutics is advancing its clinical-stage pipeline, which includes allogeneic CAR-T cell therapies for various cancers and genetic medicines targeting high unmet medical needs. Their innovative approach leverages proprietary genetic editing platforms, including a non-viral transposon-based DNA delivery system, the Cas-CLOVER™ Site-Specific Gene Editing System, and other advanced technologies. The company has formed strategic collaborations with Roche and Astellas to further their research and development efforts in cell therapies for cancer patients.

This ongoing research and the upcoming presentations at the SITC and ASH meetings underscore Poseida Therapeutics' commitment to developing innovative treatments for cancer and other severe diseases, potentially offering new hope for patients with limited treatment options.